Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363736 | 0.86 | AR (0.44) | ARCYP11B1CYP11B2TRPV4HTR2A | |
| SCHEMBL1365870 | 0.83 | AR (0.36) | ARCYP11B1CYP11B2TRPV4DAO | |
| SCHEMBL1363872 | 0.83 | AR (0.39) | ARCYP11B1CYP11B2TRPV4DAO | |
| SCHEMBL3333067 | 0.79 | AR (0.41) | ARCYP11B1CYP11B2TRPV4ESR1 | |
| SCHEMBL21910132 | 0.75 | MPO (0.38) | ARHTR2AALDH1A1 | |
| SCHEMBL14863560 | 0.75 | AR (0.38) | ARCYP11B1CYP11B2TRPV4HTR2A | |
| SCHEMBL3717737 | 0.75 | AR (0.41) | ARCYP11B1CYP11B2TRPV4DAO | |
| SCHEMBL10878832 | 0.74 | AR (0.45) | ARTRPV4HTR2AHTR2CHTR2B | |
| SCHEMBL1365376 | 0.73 | AR (0.46) | ARCYP11B1CYP11B2TRPV4HTR2A | |
| SCHEMBL28573127 | 0.72 | TRPV4 (0.39) | ARCYP11B1CYP11B2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8642632-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642632-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8592452-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010118287-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004270-A1 | Selective Androgen Receptor Modulators | AR, NR3C2, NR5A1 | AR 1/4885CYP11B1 32/4885CYP11B2 19/4885 |
| US-20100152236-A1 | Cyclic amine compound | AR, FSHR, NR5A1 | AR 1/4885CYP11B1 31/4885CYP11B2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.